Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , ... July 03, 2015 ... ... providing industry-leading products for use in applications such as animal waste reduction, ... treatment plants and restaurant kitchen settings, announced today that it will be ...
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... ... 03, 2015 , ... The Alexander Group, a 30-year old, ... alike-- typically known for its consummate professionalism-- embarks each year in a whacky ... from their day jobs. , "Our motto has always been work hard play ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis market is expected to ... The bioscience market is expected to grow at the highest CAGR of 8.46%; its ... in the research labs and academic institutions for root cause analysis of failure. The ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3The Alexander Group Declares Their Independence with a Bit of Levity 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... BELGRADE, Mont., March 18, 2011 Bacterin International ... ("Bacterin"), a creator and developer of revolutionary bone graft ... that it has agreed in terms to acquire Robinson ... primarily on maxillofacial and craniofacial surgery devices.  The proposed ...
... 2011 Warner Chilcott plc (Nasdaq: WCRX ... successfully completed the refinancing of the Company,s prior senior ... its term loan borrowings under its new senior secured ... cash on hand, to repay and terminate its prior ...
... 17, 2011 Advanced Life Sciences Holdings, Inc. (OTC Bulletin ... host a conference call and webcast discussing the Company,s 2010 ... 2011 at 9:00 AM (EDT). Michael T. Flavin, Ph.D., Chairman ... the management team, will also present an update on the ...
Cached Biology Technology:Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC 2Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC 3Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC 4Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance 2Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance 3Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance 4Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance 5Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... German . What happens if you cannot recall ... name and face of a person, yet you might be unable ... the recall of the information is temporarily impaired. How such associative ... great mysteries of modern neurobiology. Now, scientists from the Max Planck ...
... basis of the most pessimistic and severe scenarios for conditions ... 2080, the oak woods of the Basque Country ... habitat, given that, in our territory, wooded areas will not ... development. Neiker-Tecnalia experts consider that this study illustrates the tendency ...
... scombrids (tunas, bonitos, mackerels and Spanish mackerels) and billfishes ... Red List of Threatened SpeciesTM. Of the 61 known ... at serious risk of extinction. Four species are listed ... in the Least Concern category. The results show ...
Cached Biology News:How memory is read out in the fly brain 2How memory is read out in the fly brain 3Climate change may alter conditions for growth of oak trees in Euskadi 2Increased protection urgently needed for tunas 2Increased protection urgently needed for tunas 3
...
EoProbe Eosinophil Staining Kit, 1 Kit...
... kit contains the basic components required for ... natural and recombinant rat L-Selectin in cell ... contains sufficient materials to run ELISAs on ... following conditions are met: The ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Biology Products: